One Stop Solution For In-Depth Market Research Reports

詳細な市場調査レポートのワンストップソリューション

Home    >    HEALTHCARE AND PHARMACEUTICALS   >   Gastroesophageal Reflux Disease Market

[ 英語タイトル ] Gastroesophageal Reflux Disease Market - Growth, Trends, and Forecast (2020 - 2025)


Product Code : MDHC0089118
Survey : Mordor Intelligence
Publish On : November, 2020
Number of Pages : 113
Category : Healthcare and Pharmaceuticals
Study Area : Global
Report format : PDF
Sales price option (consumption tax not included)
Single User USD4250 / Question Form
5 User USD4750 / Question Form
Enterprise User USD7500 / Question Form
 - GlaxoSmithKline PLC
- SRS Life Sciences
- Johnson & Johnson
- Medtronic Plc
- Pfizer, Inc.
- Reckitt Benckiser Group Plc
- Takeda Pharmaceutical Co., Ltd.
- Teva Pharmaceuticals Industries Limited.

[Report Description]

The major factors for the growth of the gastroesophageal reflux disease market includes the rising prevalence of gastroesophageal reflux diseases and changing lifestyle, and increasing awareness about GERD.

According to the World Health Organization, in 2017, globally there are more than USD 10 billion that was found to be spent every year on antacids. As per the World Gastroenterology Organization, the prevalence rate of GERD is growing rapidly across the world. It was valued at approximately 2.5%-6.6% in South East Asia and almost 13.8%-25.8% in North America. In geriatric population, acidic complications are recurrent, which provides a unique challenge, for both, the primary care providers and gastroenterologists. Thus, rising cases of GERD the market is expected to witness high demand.

In addition, the growing number of companies for the treatment of acid reflux disorders is majorly attributable for the increase in the market.

Key Market Trends

Proton Pump Inhibitors Segment is Expected to hold the Large Market Share over the Forecast Period

- Proton pump inhibitors accounted for the second largest segment as they are the most commonly prescribed medication for the treatment of acid reflux. The Proton Pump Inhibitors (PPI) characterize the maximum potency in inhibiting gastric acid secretion, primarily by blocking the acid pump. These inhibitors are well-known, for both, therapeutic effects and good safety profiles.
- Heartburn and regurgitation are the most common acid reflux-related symptoms in Canadian patients, and many individuals self-diagnose and self-treat these symptoms. PPIs are the most successful short-term treatment for recurrent or severe heartburns. The OTC status of some PPI drugs is expected to augment their sales. Thus, owing to the all above mentioned factors the market is expected to witness a high growth.

North America is Expected to Hold the Largest Market Share over the Forecast Period

The United States is expected to be the largest market owing to the presence of better healthcare infrastructure and the rising prevalence of GERD. In the United States, tablet (chewable form) and liquid forms are most widely used. There is a rising prevalence of GERD across the world, although there are marked differences in the reported prevalence, ranging from 14% to 26% in North America.

However, it can be correlated with the rising prevalence of obesity, along with other dietary factors, in many countries. GERD can be associated with the impact on the quality of life and reduction in personal and work-related productivity. In the United States, major selling drugs include omeprazole, Pantoprazole Sodium, and Nexium. Thus, owing to the lifestyle change and rising cases of GERD the market is expected to grow.

On the other hand, the Asia Pacific region is also being projected to showcase the fastest growth rate over the forecast period due to the rising geriatric population.

Competitive Landscape

The market studied is a fragmented market owing to the presence of various market players. Some of the market players are GlaxoSmithKline PLC, Ironwood Pharmaceuticals, Inc., Johnson & Johnson Services, Inc., Medtronic Plc, Olympus Corporation, Pfizer, Inc., Reckitt Benckiser Group PLC, Takeda Pharmaceutical Co., Ltd., and Teva Pharmaceuticals Industries Limited.

Reasons to Purchase this report:

- The market estimate (ME) sheet in Excel format
- 3 months of analyst support

1 INTRODUCTION
1.1 Study Deliverables
1.2 Study Assumptions
1.3 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Rising Prevalence of Gastrointestinal Reflux Diseases and Changing Lifestyle
4.2.2 Increasing Awareness about GERD
4.3 Market Restraints
4.3.1 Patent Expiry of Blockbuster Drugs
4.4 Porter's Five Force Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION
5.1 By Product
5.1.1 Diagnosis
5.1.1.1 Upper Endoscopy
5.1.1.2 Ambulatory Acid (pH) Probe Test
5.1.1.3 Esophageal Manometry
5.1.1.4 Others
5.1.2 Drug Type
5.1.2.1 Proton Pump Inhibitors (PPIs)
5.1.2.2 H2 Receptor Blockers
5.1.2.3 Others
5.2 Geography
5.2.1 North America
5.2.1.1 United States
5.2.1.2 Canada
5.2.1.3 Mexico
5.2.2 Europe
5.2.2.1 Germany
5.2.2.2 United Kingdom
5.2.2.3 France
5.2.2.4 Italy
5.2.2.5 Spain
5.2.2.6 Rest of Europe
5.2.3 Asia Pacific
5.2.3.1 China
5.2.3.2 Japan
5.2.3.3 India
5.2.3.4 Australia
5.2.3.5 South Korea
5.2.3.6 Rest of Asia-Pacific
5.2.4 Middle East and Africa
5.2.4.1 GCC
5.2.4.2 South Africa
5.2.4.3 Rest of Middle East and Africa
5.2.5 South America
5.2.5.1 Brazil
5.2.5.2 Argentina
5.2.5.3 Rest of South America

6 COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 GlaxoSmithKline PLC
6.1.2 SRS Life Sciences
6.1.3 Johnson & Johnson
6.1.4 Medtronic Plc
6.1.5 Pfizer, Inc.
6.1.6 Reckitt Benckiser Group Plc
6.1.7 Takeda Pharmaceutical Co., Ltd.
6.1.8 Teva Pharmaceuticals Industries Limited.

7 MARKET OPPORTUNITIES AND FUTURE TRENDS

渋谷データカウント

渋谷データカウントは、最も信頼性が高く最新の調査分析レポートを確実に提供する経験豊富な調査専門家のグローバルチームが提供する、さまざまな業界のさまざまな市場調査レポートを提供する再販代理店です。

Recommended reports

+